Science Corp CEO Max Hodak Says Brain Interfaces Could End the Screen Era
Science Corp CEO Max Hodak will outline its biohybrid brain interface, PRIMA vision results and post-screen thesis at Disrupt 2026 in San Francisco in October.
Summary
Science Corp has recruited an unnamed leading neurobiologist to direct the first U.S. human trials of its biohybrid brain-computer interface. CEO Max Hodak will discuss the company’s findings and argue for adaptive, brain-driven alternatives to screens during his Beyond Screens session at Disrupt 2026. Its PRIMA retinal implant has already restored sight in people with severe vision loss by using camera-equipped glasses to beam captured scenes onto an implanted retinal chip.
Hodak began programming at six, studied biomedical engineering at Duke Pratt School of Engineering, worked in Miguel Nicolelis’ brain-computer interface lab, co-founded robotic cloud laboratory Transcriptic, and co-founded Neuralink in 2016, serving as its initial president. He founded Science Corp in 2021 to develop neural technology for vision, cognition and mobility. The company raised a $230 million Series C at a $1.5 billion valuation and is exploring implanted sensors to heal damaged brain cells, warn of seizures and possibly treat Parkinson’s disease. Disrupt runs October 13 to 15 at Moscone West in San Francisco, with more than 10,000 attendees, over 250 sessions and sustainable AI programming across six industry stages. Tickets offer savings of up to $200 through September 25, groups can save up to 30%, and exhibit-table bookings close September 18.
Positives
- PRIMA has restored sight in people with severe vision loss by transmitting camera images to a chip implanted in the retina.
- $230 million in Series C funding values Science Corp at $1.5 billion.
- The first U.S. human trials will put Science Corp’s biohybrid brain-computer interface into clinical testing under a leading neurobiologist.
- Vision, cognition and mobility are Science Corp’s primary targets for advanced neural engineering.
- More than 10,000 attendees can hear Hodak’s post-screen argument at Disrupt 2026 in San Francisco.
Risks & concerns
- First U.S. human trials place the biohybrid interface at an early clinical stage, with findings not yet publicly detailed.
- Parkinson’s disease treatment remains a possible application rather than a demonstrated result.
- Healing damaged brain cells and issuing seizure warnings remain ambitions, with no reported clinical outcomes.
- PRIMA’s reported success addresses severe vision loss, while Science Corp’s broader cognition and mobility goals remain unproven.